Moderna begins dosing in phase 1/2 study of seasonal influenza vaccine candidates
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) said the first participant has been dosed in the Phase 1/2 study of its seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.
The Company intends to enroll about 560 participants in the study.
The company's vaccines, mRNA-1020 and mRNA-1030, target two major influenza surface glycoproteins called hemagglutinin and neuraminidase antigens.

The vaccines target the strains recommended by WHO for the prevention of influenza, including seasonal influenza A/H1N1, A/H3N2 and influenza B/Yamagata and B/Victoria, the company said. 
"We expect that our platform's flexibility in targeting multiple strains coupled with our ability to manufacture quickly will facilitate production of a vaccine that matches the predominant circulating influenza strain," said Moderna's CEO, StÃ©phane Bancel. 
The company is using its mRNA platform to develop seasonal influenza vaccines.